Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Capital Expenditures (2016 - 2025)

IGC Pharma (IGC) has disclosed Capital Expenditures for 15 consecutive years, with $29000.0 as the latest value for Q3 2025.

  • Quarterly Capital Expenditures changed 0.0% to $29000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $82000.0 through Sep 2025, down 45.33% year-over-year, with the annual reading at $112000.0 for FY2025, 18.84% down from the prior year.
  • Capital Expenditures for Q3 2025 was $29000.0 at IGC Pharma, up from $8000.0 in the prior quarter.
  • The five-year high for Capital Expenditures was $582000.0 in Q4 2022, with the low at -$404000.0 in Q3 2022.
  • Average Capital Expenditures over 5 years is $48526.3, with a median of $29000.0 recorded in 2024.
  • Peak annual rise in Capital Expenditures hit 2055.56% in 2022, while the deepest fall reached 1362.5% in 2022.
  • Over 5 years, Capital Expenditures stood at $27000.0 in 2021, then surged by 2055.56% to $582000.0 in 2022, then crashed by 88.32% to $68000.0 in 2023, then plummeted by 60.29% to $27000.0 in 2024, then grew by 7.41% to $29000.0 in 2025.
  • According to Business Quant data, Capital Expenditures over the past three periods came in at $29000.0, $8000.0, and $18000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.